Q1 FY25 saw 7% revenue growth, led by HPP, while specialty and CDMO segments faced headwinds from global inventory rationalization. Multiple CapEx projects are on track, margins are improving sequentially, and the outlook remains positive for the second half of FY25.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.